KR20120051734A - 항-ｃＭＥＴ 항체 및 암의 검출과 진단을 위한 그의 용도 - Google Patents

항-ｃＭＥＴ 항체 및 암의 검출과 진단을 위한 그의 용도 Download PDF

Info

Publication number
KR20120051734A
KR20120051734A KR1020127005757A KR20127005757A KR20120051734A KR 20120051734 A KR20120051734 A KR 20120051734A KR 1020127005757 A KR1020127005757 A KR 1020127005757A KR 20127005757 A KR20127005757 A KR 20127005757A KR 20120051734 A KR20120051734 A KR 20120051734A
Authority
KR
South Korea
Prior art keywords
seq
sequence
cdr
met
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020127005757A
Other languages
English (en)
Korean (ko)
Inventor
릴리앙 고뜨쉬
알쌍드라 주앙노
Original Assignee
피에르 파브르 메디카먼트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피에르 파브르 메디카먼트 filed Critical 피에르 파브르 메디카먼트
Publication of KR20120051734A publication Critical patent/KR20120051734A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020127005757A 2009-08-21 2010-08-23 항-ｃＭＥＴ 항체 및 암의 검출과 진단을 위한 그의 용도 Withdrawn KR20120051734A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US23586409P 2009-08-21 2009-08-21
US61/235,864 2009-08-21
EP09305777A EP2287197A1 (en) 2009-08-21 2009-08-21 Anti-cMET antibody and its use for the detection and the diagnosis of cancer
EP09305777.6 2009-08-21
US34800510P 2010-05-25 2010-05-25
US61/348,005 2010-05-25

Publications (1)

Publication Number Publication Date
KR20120051734A true KR20120051734A (ko) 2012-05-22

Family

ID=41571045

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127005757A Withdrawn KR20120051734A (ko) 2009-08-21 2010-08-23 항-ｃＭＥＴ 항체 및 암의 검출과 진단을 위한 그의 용도

Country Status (19)

Country Link
US (2) US8673302B2 (enExample)
EP (2) EP2287197A1 (enExample)
JP (1) JP5951486B2 (enExample)
KR (1) KR20120051734A (enExample)
CN (1) CN102639564B (enExample)
AR (1) AR077901A1 (enExample)
AU (1) AU2010284944B2 (enExample)
BR (1) BR112012003759A2 (enExample)
CA (1) CA2769427C (enExample)
ES (1) ES2692522T3 (enExample)
IL (1) IL218202A (enExample)
IN (1) IN2012DN01322A (enExample)
MX (1) MX2012002139A (enExample)
NZ (2) NZ700437A (enExample)
RU (1) RU2582265C2 (enExample)
SG (1) SG178339A1 (enExample)
TW (1) TW201111781A (enExample)
WO (1) WO2011020925A1 (enExample)
ZA (1) ZA201202076B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
SG10201408229WA (en) 2010-08-31 2015-02-27 Genentech Inc Biomarkers and methods of treatment
KR101444837B1 (ko) 2011-06-03 2014-09-30 한국생명공학연구원 ＨＧＦ 활성을 가지는 ｃ-Ｍｅｔ에 대한 인간항체 및 이의 용도
AU2012312515A1 (en) 2011-09-19 2014-03-13 Genentech, Inc. Combination treatments comprising c-met antagonists and B-raf antagonists
KR20130036993A (ko) * 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
SG10201506881PA (en) * 2011-11-21 2015-10-29 Taivex Therapeutics Corp Biomarkers for cancers responsive to modulators of hec1 activity
SG11201402485UA (en) 2011-11-21 2014-06-27 Genentech Inc Purification of anti-c-met antibodies
GB201121914D0 (en) 2011-12-20 2012-02-01 Ge Healthcare Ltd Method for patient selection
CA2869316C (en) * 2012-05-09 2016-12-20 Eli Lilly And Company Anti-c-met antibodies
HK1208181A1 (en) * 2012-06-21 2016-02-26 Sorrento Therapeutics, Inc. Antigen binding proteins that bind c-met
WO2014128235A1 (en) 2013-02-22 2014-08-28 F. Hoffmann-La Roche Ag Methods of treating cancer and preventing drug resistance
US10214593B2 (en) 2013-04-02 2019-02-26 Samsung Electronics Co., Ltd. Anti-idiotype antibody against anti-c-MET antibody
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
WO2015031626A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Soluble cmet assay
WO2015031614A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Soluble cmet assay
WO2015032695A1 (en) * 2013-09-09 2015-03-12 Ventana Medical Systems, Inc. Scoring method for mesothelin protein expression
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
EP3122900A1 (en) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
KR20170005016A (ko) 2014-05-23 2017-01-11 제넨테크, 인크. MiT 바이오마커 및 그의 사용 방법
EP3229836B1 (en) 2014-12-09 2019-11-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Human monoclonal antibodies against axl
US10544210B2 (en) * 2015-02-03 2020-01-28 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-Rho GTPase conformational single domain antibodies and uses thereof
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
KR20170128256A (ko) * 2015-03-18 2017-11-22 시애틀 지네틱스, 인크. Cd48 항체 및 이의 접합체
EP3411067B1 (en) 2016-02-05 2021-10-20 Helixmith Co., Ltd Anti-c-met antibodies and uses thereof
RS61659B1 (sr) 2016-05-17 2021-04-29 Abbvie Biotherapeutics Inc Konjugati antitelo lek anti-cmet i metode za njihovu upotrebu
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
RU2735918C2 (ru) * 2018-06-07 2020-11-10 Общество с ограниченной ответственностью "ДЖЕЙВИС ДИАГНОСТИКС" Набор реагентов для выявления маркера эпителиальных карцином
CN112351998B (zh) * 2018-06-29 2022-07-22 苏州智核生物医药科技有限公司 Pd-l1结合多肽及其用途
KR102396194B1 (ko) * 2018-12-07 2022-05-10 서울대학교 산학협력단 항 c-Met 아고니스트 항체 및 이의 용도
US20220252603A1 (en) * 2019-06-06 2022-08-11 Apollomics Inc. (Hangzhou) Method for treating cancer patients using c-met inhibitor
CN114340684B (zh) 2019-09-16 2025-09-12 瑞泽恩制药公司 用于免疫pet成像的放射性标记的met结合蛋白
JP7510518B2 (ja) 2020-09-01 2024-07-03 レメゲン シーオー．，エルティーディー． 抗ｃ－Ｍｅｔ抗体薬物複合体及びその応用
CA3191363A1 (en) * 2020-09-08 2022-03-17 Ideaya Biosciences, Inc. Pharmaceutical combination and tumor treatment
IL315960A (en) 2022-03-30 2024-11-01 Pinetree Therapeutics Inc Bispecific antibodies comprising an nrp1 binding domain and methods of use thereof
CA3251953A1 (en) * 2022-06-09 2023-12-14 Santa Ana Bio, Inc. C-KIT AND/OR SIGLEC TARGETING ANTIBODIES AND THEIR USES
AU2023317484A1 (en) 2022-07-30 2025-03-13 Pinetree Therapeutics, Inc. Compositions for targeted lysosomal degradaton and methods of use thereof
EP4763865A1 (en) * 2023-08-14 2026-06-24 Minghui Pharmaceutical (Hangzhou) Limited Anti-c-met nanobody and use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
WO2003057155A2 (en) * 2001-12-27 2003-07-17 Van Andel Research Institute Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
WO2007056523A2 (en) * 2005-11-08 2007-05-18 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for diagnosing and monitoring the progression of cancer
ES2368864T3 (es) * 2006-02-06 2011-11-23 Metheresis Translational Research Sa Anticuerpos monoclonales anti-met, sus fragmentos y vectores para el tratamiento de tumores y productos correspondientes.
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
US7892770B2 (en) * 2007-08-24 2011-02-22 Van Andel Research Institute Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methods
AR074439A1 (es) * 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer

Also Published As

Publication number Publication date
CA2769427C (en) 2020-03-10
US8673302B2 (en) 2014-03-18
AR077901A1 (es) 2011-09-28
IL218202A (en) 2017-07-31
SG178339A1 (en) 2012-03-29
MX2012002139A (es) 2012-03-07
TW201111781A (en) 2011-04-01
EP2467402A1 (en) 2012-06-27
WO2011020925A1 (en) 2011-02-24
CN102639564A (zh) 2012-08-15
NZ700437A (en) 2016-04-29
CA2769427A1 (en) 2011-02-24
US20140295452A1 (en) 2014-10-02
EP2467402B1 (en) 2018-08-01
JP2013502213A (ja) 2013-01-24
JP5951486B2 (ja) 2016-07-13
RU2012109004A (ru) 2013-09-27
CN102639564B (zh) 2015-01-07
AU2010284944A1 (en) 2012-03-08
IN2012DN01322A (enExample) 2015-06-05
ES2692522T3 (es) 2018-12-04
EP2287197A1 (en) 2011-02-23
IL218202A0 (en) 2012-04-30
AU2010284944B2 (en) 2016-01-28
BR112012003759A2 (pt) 2017-07-11
US20120149031A1 (en) 2012-06-14
ZA201202076B (en) 2012-11-28
NZ598194A (en) 2015-05-29
RU2582265C2 (ru) 2016-04-20

Similar Documents

Publication Publication Date Title
EP2467402B1 (en) Anti-cmet antibody and its use for the detection and the diagnosis of cancer
EP2588497B1 (en) Novel antibody for the diagnosis and/or prognosis of cancer
CA2715103A1 (en) Monoclonal antibody which binds met in formalin-fixed and paraffin-embedded tissues and related methods
KR20170138466A (ko) 새로운 igf-1r 항체 및 암의 진단을 위한 그의 용도
KR102350259B1 (ko) Igf-1r 항체 및 암의 진단을 위한 그의 용도
HK1183311A (en) Novel antibody for the diagnosis and/or prognosis of cancer
HK1169420A (en) Anti-cmet antibody and its use for the detection and the diagnosis of cancer
HK1243434B (en) Igf-1r antibody and its use for the diagnosis of cancer
HK1248730B (en) Igf-1r antibody and its use for the diagnosis of cancer

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid
R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000